Markets Brace For RBI Policy And Q2 Earnings, West Asia Tensions To Guide Sentiment

Indian markets anticipate key factors this week: the Reserve Bank of India's monetary policy announcement, the release of second-quarter earnings, and ongoing developments in the Middle East following recent market declines. The Reserve Bank's decision on interest rates and its outlook for inflation and growth will heavily influence market sentiment. Company financial results will provide early insights into business performance and demand.

Investors will pay close attention to the central bank's assessment of escalating energy costs and broader price pressures. Its comments on economic growth will also be crucial as global uncertainty persists. The earnings season could generate stock-specific movements as firms report their July-September performance.

Domestic economic indicators offer some optimism. Industrial production expanded by 8% in August, a notable improvement from the upwardly revised 7.4% growth in July. Manufacturing output surged by 9%, while electricity and gas supply increased by 12.3%. However, tensions in the Middle East continue to dominate market outlooks. Analysts believe a substantial easing of conflicts in the region could trigger a significant recovery, but concerns remain over higher U.S. Treasury yields, inflation worries, and expensive energy.

Rising long-term U.S. bond yields have raised concerns about tighter global financial conditions, making emerging-market assets less attractive. FPIs (Foreign Portfolio Investors) pulled out Rs 45,536 crore in September, coinciding with a market slide. Brent crude prices have eased from recent highs as exports through the Strait of Hormuz have rebounded closer to pre-war levels. However, further movements in oil prices will remain significant triggers for market sentiment.

Key levels to monitor for the S&P 500 index include 71,909.70 for the Sensex and 22,421.95 for the Nifty, after suffering an eighth consecutive weekly decline. Aurobindo Pharma recently received final approval from the USFDA for its Perampanel tablets, with an estimated market size of ₹558 crore. Analysts view immediate resistance at 22,800 and 23,000.

A sustained rise above this range could alleviate selling pressure, while support is expected at 22,350 and 22,180. Weak momentum suggests continued downward pressure, although brief rebounds remain plausible. Investors will also closely monitor upcoming U.S. economic releases for signals on employment, manufacturing activity, and the trajectory of interest rates.